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Abstract
Human protein diversity arises as a result of alternative splicing, single nucleotide polymorphisms (SNPs) and
posttranslational modifications. Because of these processes, each protein can exists as multiple variants in vivo. Tailored
strategies are needed to study these protein variants and understand their role in health and disease. In this work we
utilized quantitative mass spectrometric immunoassays to determine the protein variants concentration of beta-2-
microglobulin, cystatin C, retinol binding protein, and transthyretin, in a population of 500 healthy individuals. Additionally,
we determined the longitudinal concentration changes for the protein variants from four individuals over a 6 month period.
Along with the native forms of the four proteins, 13 posttranslationally modified variants and 7 SNP-derived variants were
detected and their concentration determined. Correlations of the variants concentration with geographical origin, gender,
and age of the individuals were also examined. This work represents an important step toward building a catalog of protein
variants concentrations and examining their longitudinal changes.
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Introduction
Human protein diversity arises as a result of three main
processes: i) Alternative splicing, which can produce multiple
protein products from a single gene [1]; ii) Non-synonymous single
nucleotide polymorphisms (SNPs) [2] that can produce single
amino acid variations [3]; and iii) Posttranslational modifications
(PTMs) which can add or remove chemical moieties on either an
amino acid or the protein N- or C-terminus [4]. Because of these
processes, each protein can exist as multiple variants in vivo, thus
making the human proteome far more complex than the human
genome and its ,25,000 human genes. Therefore, tailored
strategies are needed to study the protein diversity and understand
its role in health and disease.
Protein variants were initially studied via gel electrophoresis.
One-dimensional gel isoelectric focusing was the method of choice,
contributing to the discovery of variants for proteins such as
hemoglobin [5], alpha-antitrypsin [6], amylase [7], and prealbu-
min (transthyretin) [8]. Subsequently, two-dimensional gel elec-
trophoresis provided increased resolving power for simultaneous
analysis of hundreds of proteins and their variants, especially when
coupled to mass spectrometric (MS) identification of the protein
spots from the gel [9]. Two-dimensional difference gel electro-
phoresis (DIGE) has been used in delineating protein variations
across populations, as shown in the study of longitudinal and
individual variation of 78 proteins from eleven healthy subjects
[10], the normal variability of the human plasma proteome from
60 healthy subjects [11], and age-related differences in 100 plasma
proteins from 42 individuals [12]. Because of dynamic range,
reproducibility and throughput limitations, 2D gel electrophoresis
was surpassed by bottom-up and top-down mass spectrometry
approaches for decoding protein modifications [13–15]. In
bottom-up approaches, proteins are digested with trypsin, and
selected reaction monitoring (SRM) or multiple reaction monitor-
ing (MRM) mass spectrometry is used to detect peptides (straight
from the human plasma, or immuno-enriched) that contain the
protein modifications. Osteopontin splice variants were identified
and quantified using MRM-MS [16]; novel proteoforms of
prostate specific antigen were also identified in clinical samples
via MRM-MS [17]. In a larger population study, the concentra-
tion of three selected single amino acid polymorphism peptides,
representing the Complement Component C7, Complement
Factor H, and Complement Component C5 proteins, were
measured by SRM-MS from 290 individuals [18]. In another
population study, serum peptide variations were studied in 500
healthy individuals using a regular MS analysis (without trypsin
digestion), but the peptides detected were exopeptidase products
derived from relatively abundant serum proteins [19].
Top-down MS approaches provide more accurate and com-
plete results for protein variants identification because there is no
prerequisite for a priori knowledge of the protein modification in
order to select the appropriate modification-specific peptide. But
analyzing and quantifying intact proteins and their modifications
with mass spectrometry can be challenging [20]. Our group has
devised a simple method termed mass spectrometric immunoassay
[21] that combines a one-step affinity protein isolation with MS
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analysis that is ideally suited for high-throughput analysis of
human plasma proteins and their variants [22]. Antibodies are
surface-immobilized in small, porous microcolumns that are fitted
at the entrance of a pipettor tip. Samples are passed through the
pipette tip repetitively until enough protein is bound to the
antibody. Following washing with buffer and/or other mild
solutions to remove non-specifically bound sample components,
the proteins are eluted with a small volume of matrix solution and
deposited directly onto a MALDI target for ensuing MS analysis.
We’ve applied this approach to investigate the diversity of 25
human plasma proteins from a cohort of 96 healthy individuals,
resulting in the detection of 76 structural variants, each occurring
with different frequencies [23]. Subsequently, we’ve screened
1,000 individuals from four geographical regions in the United
States, and determined the variants and their frequencies for five
proteins - beta-2-microglobulin, cystatin C, retinol binding
protein, transferrin, and transthyretin [24]. The qualitative data
from those studies provided a first glimpse into the extent of
protein structural diversity in the general population.
Recently we have developed and validated fully quantitative
mass spectrometric immunoassays for 4 of those clinically relevant
proteins - beta-2-microglobulin [25], cystatin C [26], retinol
binding protein [27] and transthyretin [28]. Beta-2-microglobulin
is used in the diagnosis of active rheumatoid arthritis and kidney
disease [29,30], and a structural variant of b2m has been
associated with autoimmune disease and small-cell lung cancer
[31,32]. Cystatin C is a serine proteinase inhibitor with
implications in renal failure [33,34]. Retinol binding protein has
also been implicated in renal disease [35], with the increased
presence of its truncated variants suggested as indication of renal
failure [36]. Transthyretin has been associated with systemic
amyloidoses and familial amyloidotic polyneuropathy [37,38],
primarily as a result of its more than 80 SNPs [39]. The mass
spectrometric immunoassays for these 4 proteins were designed to
detect and quantify individual protein variants. In this work we’ve
applied these four quantitative assays to determine the concentra-
tion of all variants we can detect in 500 healthy individuals.
Additionally, we determined the longitudinal concentration
changes over a 6 month period for those variants in four
individuals.
Materials and Methods
Reagents
Polyclonal rabbit anti-human antibodies to beta-2-microglobu-
lin (b2m, Cat. No A0072, 5.7 g/L), cystatin C (cysC, A0451, 17 g/
L), retinol binding protein (RBP, A0040, 4.1 g/L), and transthy-
retin (TTR, A0002, 3.9 g/L) were obtained from DAKO
(Carpinteria, CA, USA). Rabbit anti-human polyclonal antibody
to beta-lactoglobulin (BL) was obtained from GeneTex (Irvine,
CA, GTX77272, 1 mg/mL). Recombinant human beta-2-
microglobulin (b2m) was purchased from Cell Sciences (Canton,
MA, CSI19620). Recombinant human cystatin C (cysC) was
purchased from HyTest (Turku, Finland, 8CY5). Purified human
retinol binding protein (RBP) was purchased from Sigma (St.
Louis, MO, R9388). Beta-lactoglobulin from bovine milk (L8005),
1,19 Carbonyldiimidazole (115533), TWEEN 20 (P7949), TRIS
(T-6128), and a-cyano -4-hydroxycinnamic acid (476870) were
Figure 1. Proteins and their variants detected among the 500 individuals. Green: native proteins; Yellow: posttranslational modifications;
Purple: SNP-derived variants.
doi:10.1371/journal.pone.0100713.g001
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obtained from Sigma-Aldrich (St. Lous, MO). Sinapinic acid (3-(4-
hydroxy-3,5-dimethoxyphenyl)prop-2-enoic acid)was purchased
from Fluka (Cat. No. 85429). Affinity pipettes fitted with porous
microcolumns were obtained from Intrinsic Bioprobes (Tempe,
AZ, IBI-CMD-R96). Phosphate buffered saline (PBS) was
obtained from Thermo Scientific (Rockford, IL, 28374). HBS-
EP buffer (0.01 M HEPES pH 7.4; 0.15 M NaCl, 3 mM EDTA,
0.005% v/v Surfactant P20) was obtained from GE Healthcare
(Piscataway, NJ). Sterile water (AB02120), acetone (AB00636),
MES (AB01235), acetonitrile (AB00120) and trifluoracetic acid
(AB02010) were purchased from American Bionalytical (Natick,
MA). 1-Methyl 2-pyrrolidone was obtained from EMD Chemicals
(Gibbstown, NJ, MX1932-5). N-octylglucoside was obtained from
Roche Applied Science (Indianapolis, IN, 10634425001). Se-
quencing grade modified trypsin was obtained from Promega
(Madison, WI, V511). Sequencing grade endoproteinase Arg-C
was obtained from Roche Applied Science (Penzberg, Germany,
11370529001).
Human plasma samples
Five hundred sodium heparin human plasma samples were
obtained from ProMedDX (Norton, MA, USA), and were
designated as normal based on their non-reactivity for common
blood infectious agents and the donor information itself. The
samples originated from two states: Tennessee (TN, 247 samples,
210 male, 37 female, median age 37), and Texas (TX, 253
samples, 201 males, 52 females, median age 36). The samples were
received labeled only with a barcode and supplied with an
accompanying specification sheet containing information about
the gender and age. For the longitudinal study, human capillary
blood was obtained once a week (fasting morning blood draw), for
twenty seven weeks, from 4 individuals (three males, one female,
median age 36). Each individual had signed an Informed Consent
Form. This study was approved by Intrinsic Bioprobes’ Institu-
tional Review Board (IRB No. 00001399). Seventy-five microliters
of blood were drawn under sterile conditions from a lancet-
punctured finger with heparinized microcolumn (Drummond
Scientific Co., Broomal, PA), and centrifuged for 60 s at 2,500g to
pellet red blood cells. The supernatant plasma was stored at 2
80uC until used.
Assay execution and data analysis
The antibody-derivatized affinity pipettes, analytical solutions of
the proteins for the standard curves, internal reference standard
(beta lactoglobulin), plasma samples dilutions, and analytical
samples solutions, were prepared as described previously for each
of the four assays [25–28]. The antibody-derivatized affinity
pipettes were mounted onto the head of a Multimek 96 automated
96-channel pipettor (Beckman Coulter, Brea, CA) and initially
rinsed with assay buffer (PBS or HBS-EP, 10 aspirations and
dispense cycles, 100 mL volumes each). Next, the pipettes were
immersed into a microplate containing the samples and 100
aspirations and dispense cycles (200 for RBP) were performed (100
mL volumes each) allowing for affinity capture of the targeted
proteins. The pipettes were then rinsed with assay buffer (100
cycles), and twice with water (10 cycles each). For elution of the
captured proteins, 6 mL aliquots of MALDI matrix (25 g/L a-
cyano-4-hydroxycinnamic acid, or 13.3 g/L sinapinic acid, in
aqueous solution containing 33% (v/v) acetonitrile, and 0.4% (v/
v) trifluoroacetic acid) were aspired into the affinity pipettes, and
after a 10 second delay (to allow for the dissociation of the protein
from the capturing antibody), the eluates from all 96 affinity
pipettes containing the targeted proteins were dispensed directly
onto a 96-well formatted MALDI target. Following air-drying and
visual inspection of the sample spots, linear mass spectra were
acquired on an Autoflex II MALDI-TOF mass spectrometer
(Bruker, Billerica, MA), with a delayed extraction mode using a
1.7 kV draw out pulse, 200 ns delay, and a full accelerating
potential of 20 kV. Five mass spectra were acquired from each
sample spot (to gain representative sample data), each spectrum
consisting of three-hundred laser shots. The mass spectra were
processed (baseline subtracted and smoothed) with Flex Analysis
software (Bruker).
We measured peak heights and used them for quantification.
The peak heights for the protein signals and the internal reference
standard (beta lactoglobulin - BL) were determined from each
spectrum and entered into an Excel spreadsheet. The protein/BL
peak heights ratios were calculated, and the average protein/BL
ratio for each sample was determined from the five mass spectra. A
standard curve was generated for each protein by plotting the
average standard protein/BL ratios against the concentration of
the protein standards, and the data was fitted with a linear
trendline using Sigma Plot (Systat Software, San Jose, CA). The
standard curves were then utilized to determine the concentration
of the four proteins and their variants in the analytical samples.
We first determined the protein/BL peak heights ratios for each
variant, summed up the ratios of all variants for an individual
protein, determined the total individual protein concentration
using the corresponding standard curve, and then determined the
concentration of each variant based on its percentage of the total
protein concentration. This approach worked especially well for
Table 1. Molecular weights of the observed proteins and their
variants.
Protein Molecular Weight
Beta-2-microglobulin 11,732.0
des-K58 beta-2-microglobulin 11,618.0
Cystatin C 13,343.1
Cystatin C 3Pro-OH 13,359.0
Cystatin C des-S 13,256.0
Cystatin C des-SSP 13,071.8
Cystatin C mutation 13,315.2
Retinol binding protein 21,065.5
Retinol binding protein des-L 20,952.4
Retinol binding protein des-LL 20,839.2
Retinol binding protein des-RNLL 20,568.9
Retinol binding protein des-SERNLL 20,352.7
Transthyretin 13,761.4
Transthyretin cysteinylation 13,880.4
Transthyretin Cys10Gly 13,715.4
Transthyretin oxidation 13,793.4
Transthyretin sulfonation 13,841.4
Transthyretin CysGly 13,937.4
Transthyretin Val122Ile 13,775.4
Transthyretin His90Asn 13,738.4
Transthyretin Ala109Val 13,789.4
Transthyretin Arg104His 13,742.4
Transthyretin Ala109Thr 13,791.4
Transthyretin Gly6Ser 13,791.4
doi:10.1371/journal.pone.0100713.t001
Human Protein Variants Concentration and Longitudinal Change
PLOS ONE | www.plosone.org 3 June 2014 | Volume 9 | Issue 6 | e100713
those variants whose variant/BL peak ratios were below those of
the standard curve. Each sample was analyzed in duplicates, at
two various dilutions, and the final concentrations were deter-
mined as an average of the two measurements (if the two
measurements were significantly different, the assays were
repeated). For identification of the TTR variants, enzymatic
digestion with trypsin and endoproteinase Arg-C was performed in
situ directly on the TTR eluates deposited onto the MALDI target
after the mass spectrometric immunoassay of the human serum
samples, as described in the TTR assay development paper [28].
Reflectron mass spectra were acquired on an Autoflex II TOF/TOF
MALDI-TOF mass spectrometer (Bruker, Billerica, MA), with a
delayed extraction mode, using a 2.1 kV draw out pulse, 1100 ns
delay, an ion mirror voltage of 20 kV, and a full accelerating
potential of 19 kV.
Results and Discussion
Summarized in Fig. 1 and Table 1 are all the protein variants
detected with the four assays, and their frequency among the 500
individuals. Along with the native forms of the four proteins, 13
posttranslationally modified variants and 7 SNP-derived variants
were detected, for a total of 24 distinct protein species. For b2m
only one posttranslationally modified form was detected –
generated by the cleavage at position 58 in the amino acid
sequence and removal of Lys58 (des-K58) [40]. This variant was
detected in 12 individuals (2.4% of the samples), which is in
agreement with our previous observations of 2–6% occurrence in
the normal population [23,24]. Cystatin C was detected in its
native form and as 3 posttranslationally modified variants in all
500 samples: one variant contained hydroxyproline at position 3
(3Pro-OH) [41], and two others contained truncated sequences –
the first one missing its N-terminal serine (des-S), and the second
one missing three N-terminal residues (des-SSP). An SNP-derived
variant was also detected for cysC, as evidenced by a shift of -30Da
in the mass spectra. This SNP was observed only in male subjects,
as in our previous work, and with similar frequencies [23,24].
Retinol binding protein was observed as 4 posttranslationally
modified variants, derived by C-terminal truncation of Leu (des-L),
Figure 2. Individual concentrations of (a) b2m, (b) CysC, (c) RBP, and (d) TTR, and their variants among the 500 individuals. Box - 25-
75th percentile; Solid line – median concentration; Short dash line – mean concentration; Error bars – 10th and 90th percentile; Symbols – outlying
points.
doi:10.1371/journal.pone.0100713.g002
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Leu-Leu (des-LL), Arg-Asn-Leu-Leu (des-RNLL), and Ser-Glu-
Arg-Asn-Leu-Leu (des-SERNLL). The frequencies of these vari-
ants in the 500 samples matched those observed in our previous
studies [23,24]. Finally, TTR exhibited the most diversity. Five
posttranslationally modified variants were observed in most
samples, resulting from the reactive Cys10 residue that yielded
variants with cysteinylation, cysteine10glycine transformation
(Cys10Gly), oxidation, sulfonation, and cysteinyl-glycine (CysGly).
In addition, six SNP-derived variants were observed for TTR, and
confirmed via enzymatic in situ digestion. All of the SNPs have
been described previously [39]. Of note, the Gly6Ser variant was
observed in 32 samples (6.4%), which is in a very good agreement
with the previous results that yielded frequencies of 7% [23] and
5.6% [24]. Representative mass spectra depicting the protein
variants are shown in Fig. S1.
Using standard curves (examples of which are shown in Fig. S2)
we determined the individual concentrations of each native
protein and its variants in the 500 individuals. The data are
presented in Fig. 2 as box plots with the statistical measurements
of median, mean, 25th and 75th percentile, 90th and 10th
percentile, and outlying points. For b2m and RBP, the native
protein was present at the highest concentration, and was by far
the most dominant form of the protein. For cysC and TTR,
however, the 3Pro-OH and the cysteinylated variants, respectively,
were the most abundant species; the native forms of these two
proteins were only a small fraction of the total proteins present in
vivo. Considering the total protein concentrations (obtained by
summing up the concentration of the native form and the
variants), the values obtained were well within the reference range
for each protein in a healthy population: ,2 mg/L for b2m [30],
,0.85 mg/L for cysC [42], ,40 mg/L for RBP [43], and 150–
250 mg/L for TTR [44], all determined by traditional enzymatic
immunoassays.
The concentration data were further parsed in regards to the
geographical origin (state), gender, and age of the individuals. The
500 human plasma samples were obtained from 411 male (M) and
89 female (F) individuals; the median and mean ages of all the
individuals were 36 and 37, correspondingly; 247 samples were
Figure 3. Concentrations of b2m and its des-K58 variant
among the 500 individuals as a function of the state of origin
(TN and TX).
doi:10.1371/journal.pone.0100713.g003
Figure 4. Concentrations of TTR and its variants among the 500 individuals as a function of the state of origin (TN and TX).
doi:10.1371/journal.pone.0100713.g004
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collected at hospitals in Tennessee (TN), and 253 in Texas (TX).
Several interesting correlations were derived for these attributes.
For b2m, the des-K58 variant was present in a small number of
samples (twelve), at very low concentration, and only in individuals
from TX (Fig. 3). Even though the TX samples had on average
higher native b2m concentration, the presence of the des-K58
b2m variant was not related to the total expression of b2m, as the
des-K58 variant appeared in individuals with total b2m concen-
tration ranging from 1.28 to 2.98 mg/L. All cysC variants were
present at slightly elevated concentrations in the samples from TX,
and the same trend was observed for the native form of RBP (Fig.
S3). This elevated protein concentrations in the TX samples was
most prominent for TTR where the concentration of the
sulfonated variant was much higher than that seen in the TN
samples (Fig. 4). It seems very unlikely that the individuals from
Texas have truly elevated forms of these proteins. Because both
the TN and TX samples were collected in the same time period
(TN: January-February 2009; TX: March-April 2009), a more
likely explanation is that the samples were handled somewhat
differently – either the collection tubes were from a different
manufacturer, or the plasma samples were stored differently post-
collection before being placed at 280uC for long term storage.
Whatever the cause, the evaluation of the data points out that
standardized sample collection and storage protocols are impor-
tant, because today’s MS-based techniques can easily reveal the
slightest differences due to non-conformity and deviations from the
standard sample-handling protocols.
In regards to the gender of the individuals (Fig. S4), slightly
elevated levels in native cysC and its 3Pro-OH variant were seen
in males compared to females, with the same trend observed for
Figure 5. Concentrations of b2m and its des-K58 variant
among the 500 individuals as a function of age.
doi:10.1371/journal.pone.0100713.g005
Figure 6. CysC variants longitudinal concentration profiles for the four individuals over a 27-week period.
doi:10.1371/journal.pone.0100713.g006
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native and des-L RBP. As for the age, shown in Fig. 5 is the
concentration distribution of b2m and its des-K58 variant as a
function of age. There isn’t any significant age correlation, and
similar observations were made for the other three proteins and
their variants in regards to the age of the individuals (Fig. S5).
For the longitudinal study of the protein variants, we enrolled 4
individuals and collected heparinized plasma samples once a week,
for twenty seven weeks, from a fasting morning blood draw. We
analyzed the samples (28 time points per individual) with the four
assays and determined the concentration of all protein variants.
Presented in Fig. 6 are the cysC variants longitudinal concentra-
tion profiles for the four individuals. The concentrations of all
cysC forms oscillate as much as two-fold, although the values are
well within the normal concentration range for totals cysC (as
measured by ELISAs). The profiles for the other 3 proteins are
shown in Fig. S6. Notably, none of the individuals exhibited the
des-K58 b2m variant, nor any of the SNP-derived variants of
TTR.
To the best of our knowledge, this is the first detailed study of
protein variants, their concentration range, and longitudinal
change among a larger cohort from a healthy population. This
study was made possible by the high-throughput method of mass
spectrometric immunoassay. In practice, mass spectrometric
immunoassays are no more complicated than standard enzymatic
immunoassays (i.e. ELISAs): the first step (immunoaffinity capture)
is identical; the difference is in the secondary, detection step. The
use of mass spectrometry enables unambiguous protein variants
detection, which enzymatic immunoassays cannot do. However,
the key to a successful implementation of MS for larger scale
population studies of proteins and their variants is the sample-MS
interface, that is, the presentation of the proteins for MS detection.
Several methodologies exist in that regard: in one approach, the
entire human sample is fractionated via LC/LC separations before
introduction into the mass spectrometer [45]; in another, the
entire sample is proteolyzed and 1–2 surrogate peptides are
detected with MS for protein quantification [46]; yet another
approach utilizes immuno-retrieval of intact proteins, only to
subsequently proteolyze them for surrogate peptide identification
[47]. However, identification of proteins via surrogate peptides
precludes detection of protein variants not known a priori.
Therefore, it is advantageous to interrogate intact (native) proteins.
The single-step immunoaffinity capture provided a seamless
interface between the sample and the mass spectrometer: the
process was fast (,30 min per batch of 96 samples), multiplexed
(96 samples at a time), and cost-effective (similar to ELISAs - the
only reagents used were the affinity tips, protein and IRS
standards, and the antibodies). The use of polyclonal antibodies
assured affinity-retrieval of all variants of the targeted proteins,
and the subsequent MALDI-TOF MS analysis presented all
variants in a single spectrum.
Detection and quantification of intact proteins provides a full
view of the function of the protein (e.g., binding activity,
degradation, etc.), and in-vivo state of the protein (e.g., presence
of protein variants as a result of SNPs and posttranslational
modifications). The protein variants question is especially intrigu-
ing, ever since ‘‘only’’ ,25,000 genes have been found to be
present in the human genome. Hence, protein diversity play an
important role in biological processes, and it is imperative that we
engage in its study and delineation. Some protein variants are
common, perhaps even ubiquitous. There is already abundant
evidence to suggest that some protein variants play distinct
biological roles and are critical to the process of health and/or
disease. As with the native proteins themselves, there is a great
need for reference values for these protein variants that are
representative of healthy humans, and that are presented in a
manner that can be utilized by all laboratories [48]. We consider
this work to represent the first such step toward building a catalog
of protein variants concentration ranges and their longitudinal
change among the healthy population.
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